Colorectal Cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is one of the deadliest malignancies worldwide and a serious threat to human health. The morbidity rate and mortality rate of CRC are both rising in recent years, and the prevalence has increased with age. Generally, the aging of population and prevalent poor lifestyles are major contributing factors to CRC, and the lack of exercise, obesity, and smoking also contribute to a significantly increased risk of colorectal cancer.

The treatments for colorectal cancer include surgery, radiotherapy, chemotherapy and targeted therapy. Early stage cancer can be cured by surgery, while advanced metastatic cancer is usually treated with chemotherapy combined with targeted therapy. Studies have shown that dysregulation of several signaling pathways and targets are related to colorectal cancer, such as: VEGFR, EGFR, Wnt/β-catenin, p53, TGF-β, etc.

The TargetMol Anti-Colorectal Cancer Compound Library is a collection of 1565 compounds related to colorectal cancer, including compounds that have been reported to have therapeutic effects in colorectal cancer, as well as compounds targeting colorectal cancer-related targets, and is a good tool for anti-colorectal cancer drug development.